Trelegy Ellipta is a once-daily, single inhaler triple therapy used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) [1][2]. It combines three medications: fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta2-adrenergic agonist) [2]. This combination helps to reduce exacerbations and improve lung function in individuals with COPD [1].
How does Trelegy work for COPD?
Trelegy addresses COPD through its three active components. Fluticasone furoate works by reducing inflammation in the airways, which is a significant factor in COPD. Umeclidinium relaxes the muscles around the airways, making it easier to breathe. Vilanterol also helps to open the airways by relaxing the muscles. Together, these actions help to prevent symptoms and reduce the frequency of COPD exacerbations [2][3].
When is Trelegy prescribed for COPD?
Trelegy is typically prescribed for patients with COPD who are already on a maintenance treatment regimen with an inhaled corticosteroid and a long-acting beta-agonist, or a long-acting muscarinic antagonist and a long-acting beta-agonist, but continue to experience symptoms or exacerbations [1]. It is not intended for use as a rescue inhaler to treat sudden breathing problems [2].
What are the active ingredients in Trelegy?
The active ingredients in Trelegy Ellipta are fluticasone furoate, umeclidinium, and vilanterol [2].
How does Trelegy compare to other COPD treatments?
Trelegy offers a triple therapy approach in a single inhaler, which can simplify treatment regimens for patients compared to using multiple inhalers. Its efficacy in reducing exacerbations and improving lung function has been demonstrated in clinical trials [1]. Other COPD treatments include dual bronchodilators, inhaled corticosteroids alone, or combinations of two of the medication classes found in Trelegy [4]. The choice of treatment depends on the individual patient's disease severity, symptom burden, and history of exacerbations [4].
What are the potential side effects of Trelegy?
Common side effects associated with Trelegy include nasopharyngitis (common cold symptoms), headache, pneumonia, and bronchitis [2]. It is important for patients to discuss any concerns about side effects with their healthcare provider [2].
When does the patent for Trelegy expire?
Information on specific patent expiry dates for Trelegy can be found through resources that track pharmaceutical patents. DrugPatentWatch.com provides detailed patent information for medications [5].
What are the risks of using Trelegy?
Like all inhaled medications, Trelegy carries risks. These include an increased risk of pneumonia in patients with COPD, paradoxical bronchospasm, and certain cardiovascular effects. Patients with certain medical conditions may also be at higher risk [2]. Healthcare providers assess individual patient risks before prescribing Trelegy.
Can Trelegy be used for asthma?
Trelegy Ellipta is approved for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled on a previously initiated fluticasone furoate/vilanterol combination product or who require a treatment with all three medications [2]. It is not indicated for the relief of acute bronchospasm [2].
---
Sources:
[1] https://www.trelegy.com/
[2] https://www.trelegy.com/about-trelegy/what-is-trelegy/
[3] https://www.trelegy.com/mechanism-of-action/
[4] https://www.copdfoundation.org/index.php?page=204
[5] https://drugpatentwatch.com/